SG11201508447TA - Expression process - Google Patents

Expression process

Info

Publication number
SG11201508447TA
SG11201508447TA SG11201508447TA SG11201508447TA SG11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA
Authority
SG
Singapore
Prior art keywords
expression process
expression
Prior art date
Application number
SG11201508447TA
Inventor
Fay Louise Saunders
Anna Louise Dodds
Adeline Marie Geraldine Bayard
Bhupendra Vallabh Kara
Original Assignee
Fujifilm Diosynth Biotechnologies Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201308017A external-priority patent/GB201308017D0/en
Priority claimed from GB201320339A external-priority patent/GB201320339D0/en
Application filed by Fujifilm Diosynth Biotechnologies Uk Ltd filed Critical Fujifilm Diosynth Biotechnologies Uk Ltd
Publication of SG11201508447TA publication Critical patent/SG11201508447TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
SG11201508447TA 2013-05-03 2014-04-29 Expression process SG11201508447TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201308017A GB201308017D0 (en) 2013-05-03 2013-05-03 Expression process
GB201320339A GB201320339D0 (en) 2013-11-18 2013-11-18 Expression Process
PCT/GB2014/000165 WO2014177826A1 (en) 2013-05-03 2014-04-29 Expression process

Publications (1)

Publication Number Publication Date
SG11201508447TA true SG11201508447TA (en) 2015-11-27

Family

ID=50639794

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508447TA SG11201508447TA (en) 2013-05-03 2014-04-29 Expression process

Country Status (12)

Country Link
US (3) US9873891B2 (en)
EP (1) EP2992104B1 (en)
JP (1) JP6545153B2 (en)
KR (1) KR102180660B1 (en)
CN (2) CN114395584A (en)
BR (1) BR112015027373A2 (en)
CA (1) CA2910877C (en)
DK (1) DK2992104T3 (en)
ES (1) ES2732907T3 (en)
RU (1) RU2731717C2 (en)
SG (1) SG11201508447TA (en)
WO (1) WO2014177826A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323826A1 (en) * 2016-11-21 2018-05-23 Danmarks Tekniske Universitet Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides
EP3725877A4 (en) 2017-12-11 2021-02-17 FUJIFILM Corporation Animal cells, method for producing animal cells, and method for producing target protein
EP3896168A4 (en) 2018-12-11 2022-03-02 FUJIFILM Corporation Animal cells, method for producing animal cells, and method for producing target protein
CN109837277A (en) * 2019-03-01 2019-06-04 深圳生生凡非基因技术有限公司 A kind of CPGK chimeric promoters, gland relevant viral vector and its application
JP7352650B2 (en) 2019-11-29 2023-09-28 富士フイルム株式会社 Cell culture method, antibody production method, organic acid removal method, and antibody
WO2022149607A1 (en) 2021-01-07 2022-07-14 富士フイルム株式会社 Cell selection method, device and device system
EP4310175A1 (en) 2021-03-17 2024-01-24 FUJIFILM Corporation Cell culturing method, and method for producing useful substance
CN112980852B (en) * 2021-05-18 2021-08-13 北京华芢生物技术有限公司 Novel coronavirus B.1.351 south Africa mutant RBD gene and application thereof
KR20240014479A (en) 2021-05-27 2024-02-01 얀센 바이오테크 인코포레이티드 Compositions and methods for treating prostate cancer
WO2023054556A1 (en) 2021-09-30 2023-04-06 富士フイルム株式会社 Cell culturing method and production method for useful substance
WO2023238949A1 (en) * 2022-06-10 2023-12-14 富士フイルム株式会社 Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, cho cells, and cell pool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093295A2 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill Secretion signal vectors
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
CN101646775B (en) * 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 For producing method and the carrier of asialylated immunoglobulins
KR101618767B1 (en) * 2008-09-02 2016-05-09 한국생명공학연구원 Effective leader sequences needed for high expression of heterologous proteins
CA2746350C (en) * 2008-12-31 2018-06-12 Bharat Serums And Vaccines Ltd. Anti-rhd monoclonal antibodies
KR101579771B1 (en) 2009-03-05 2015-12-28 애브비 인코포레이티드 IL-17 binding proteins
GB0905331D0 (en) * 2009-03-27 2009-05-13 Avecia Biolog Ltd Expression process
KR101420274B1 (en) * 2011-06-13 2014-07-21 주식회사 종근당 Animal Expression Vectors Carrying CSP-B 5' SAR Factor and Methods for Preparing Recombinant Proteins Using the Same

Also Published As

Publication number Publication date
CN114395584A (en) 2022-04-26
RU2731717C2 (en) 2020-09-08
US9873891B2 (en) 2018-01-23
CN105392889A (en) 2016-03-09
RU2015151626A3 (en) 2018-03-20
JP2016517691A (en) 2016-06-20
CA2910877C (en) 2021-08-03
JP6545153B2 (en) 2019-07-17
US20220213500A1 (en) 2022-07-07
US20180127777A1 (en) 2018-05-10
ES2732907T3 (en) 2019-11-26
RU2015151626A (en) 2017-06-08
BR112015027373A2 (en) 2017-08-29
WO2014177826A1 (en) 2014-11-06
EP2992104B1 (en) 2019-04-17
KR102180660B1 (en) 2020-11-19
US11306323B2 (en) 2022-04-19
US20160076051A1 (en) 2016-03-17
EP2992104A1 (en) 2016-03-09
CA2910877A1 (en) 2014-11-06
KR20160003705A (en) 2016-01-11
DK2992104T3 (en) 2019-07-15

Similar Documents

Publication Publication Date Title
GB201312991D0 (en) Process
SG11201508447TA (en) Expression process
GB201307334D0 (en) Process
HK1220983A1 (en) Process
GB201321440D0 (en) Process
GB201416005D0 (en) Process
GB201322454D0 (en) Process
GB201421428D0 (en) Process
GB201401963D0 (en) Process
GB201318888D0 (en) Process
GB201421426D0 (en) Process
GB201401922D0 (en) Process
GB201322273D0 (en) Process
GB201314334D0 (en) Process
GB201302441D0 (en) Process
IL239449A0 (en) Process
GB201415000D0 (en) Improved process
GB201320869D0 (en) Process
GB201322992D0 (en) New Process
GB201307327D0 (en) Process
GB2520796B (en) Process
GB201323151D0 (en) Process
GB201317756D0 (en) New process
GB201313211D0 (en) New process
GB201307951D0 (en) Process